-
公开(公告)号：EP1910573A2
公开(公告)日：2008-04-16
申请号：EP06788240.7
申请日：2006-07-21
发明人： OLSON, William, C. , MADDON, Paul, J. , PEVEAR, Daniel, C. , ISRAEL, Robert, J. , MURGA, Jose, D.
CPC分类号： A61K39/39 , A61K31/351 , A61K31/4178 , A61K31/46 , A61K31/496 , A61K31/506 , A61K31/551 , A61K31/7072 , A61K38/1709 , A61K38/195 , A61K39/39541 , A61K39/3955 , A61K2039/505 , A61K2039/55511 , C07K16/2866 , C07K2317/24 , C07K2317/76 , C12Q1/701 , A61K2300/00
摘要： This method provides a method for reducing HIV-I viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-I viral load- reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-I -associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-I to CCR5+CD4+ target cells in the subject. This invention also provides a method for treating a subject infected with HIV-I comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4+ cells and (ii) inhibits fusion of HIV-I to the subject's CCR5+CD4+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.
-
公开(公告)号：EP1733057A2
公开(公告)日：2006-12-20
申请号：EP05760512.3
申请日：2005-03-25
IPC分类号： C12Q1/68
CPC分类号： G01N33/5767 , C07K16/109 , C07K16/2851 , C12Q1/6883 , C12Q2600/136 , C12Q2600/156 , G01N2500/00
摘要： This invention concerns methods for determining whether an agent preferentially binds to at least one allelic variant of L-SIGN. The invention is also directed to agents that preferentially bind to at least one allelic variant of L-SIGN. The invention also provides methods and agents for treating and preventing disorders associated with infection by pathogens, including hepatitis C virus, that bind to particular L-SIGN allelic variants. The invention further provides methods for predicting the resistance or susceptibility of a subject to pathogen infection.
-
公开(公告)号：EP1687325A2
公开(公告)日：2006-08-09
申请号：EP04818701.7
申请日：2004-11-09
CPC分类号： C07H21/02 , A61K2039/5258 , C07H21/04 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2740/13023 , C12N2740/13043 , C12N2740/13045 , C12N2770/24222 , C12N2770/24234 , C12N2810/609 , C12Q1/707
摘要： The present invention concerns a modified nucleic acid molecule comprising a nucleotide sequence coding for a full length hepatitis C virus (HCV) glycoprotein selected from the group consisting of E1 glycoprotein and E1/E2 glycoprotein heterodimer, this molecule having at least one nucleotide alteration, wherein, due to this alteration, at least one RNA splice site selected from the group consisting of RNA splice acceptor and RNA splice donor sites is eliminated from the coding sequence. The invention is also directed to methods for expressing on the surface of a cell and a pseudovirion an HCV glycoprotein, wherein the majority of the glycoprotein is full length. The invention further provides a cell and a pseudovirion expressing such glycoprotein. The invention still further provides a method for determining whether an agent inhibits HCV fusion with and entry into a target cell. The invention also provides an agent that inhibits HCV fusion with and entry into a target cell. The invention further provides methods for treating a subject afflicted with an HCV-associated disorder, for preventing an HCV infection in a subject, and for inhibiting in a subject the onset of an HCV-associated disorder.
-
公开(公告)号：EP1322332A2
公开(公告)日：2003-07-02
申请号：EP01970984.9
申请日：2001-09-14
IPC分类号： A61K39/395 , G01N33/542 , C12Q1/70 , C07K16/00
CPC分类号： C07K16/2866 , A61K38/16 , A61K39/39541 , A61K45/06 , A61K2300/00
摘要： This invention provides a composition which comprises an admixture of three compounds, wherein: a) one compound is an antibody which binds to a CCR5 receptor; b) one compound retards attachment of HIV-1 to a CD4+ cell by retarding binding of HIV-1 gp120 envelope glycoprotein to CD4 on the surface of the CD4+ cell; and c) one compound retards gp41 from adopting a conformation capable of mediating fusion of HIV-1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate; wherein the relative mass ratio of any two of the compounds in the admixture ranges form about 100:1 to about 1:100, the composition being effective to inhibit HIV-1 infection of the CD4+ CELL. This invention also provides a method of inhibiting HIV-1 infection of a CD4+ cell which comprises contacting the CD4+ cell with an amount of the composition of the subject invention effective to inhibit HIV-1 infection of the CD4+ cell so as to thereby inhibit HIV-1 infection of the CD4+ cell.
-
公开(公告)号：EP1009435A1
公开(公告)日：2000-06-21
申请号：EP98931261.6
申请日：1998-06-12
IPC分类号： A61K45/05 , A61K39/00 , A61K39/385 , C12Q1/70 , G01N33/53 , G01N33/536 , G01N33/542 , G01N33/567 , C07K14/52 , C07K14/54 , C07K17/00
CPC分类号： C07K14/005 , A61K38/00 , C07K14/522 , C07K14/523 , C07K14/70514 , C07K14/7158 , C12N2740/16122 , G01N33/566 , G01N33/56988 , G01N33/6854 , G01N2333/162 , G01N2333/70514 , G01N2333/715 , G01N2500/00 , G01N2500/20
摘要： This invention provides methods for inhibiting fusion of HIV-1 to CD4+ cells which comprise contacting CD4+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4+ cells is inhibited. This invention also provides methods for inhibiting HIV-1 infection of CD4+ cells which comprise contacting CD4+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4+ cells is inhibited, thereby inhibiting the HIV-1 infection. This invention provides non-chemokine agents capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4+ cells. This invention also provides pharmaceutical compositions comprising an amount of the non-chemokine agent capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4+ cells effective to prevent fusion of HIV-1 to CD4+ cells and a pharmaceutically acceptable carrier.
-
公开(公告)号：EP0956044A1
公开(公告)日：1999-11-17
申请号：EP97930120.0
申请日：1997-06-13
发明人： ALLAWAY, Graham, P. , DRAGIC, Tatjana , LITWIN, Virginia, M. , MADDON, Paul, J. , MOORE, John, P. , TRKOLA, Alexandra, Aaron Diamond AIDS Res. Centre
IPC分类号： A01K67 , A61K38 , A61K39 , A61K45 , A61K47 , A61P31 , A61P43 , C07K14 , C07K16 , C12N5 , C12N15
CPC分类号： C07K14/7158 , A01K2217/05 , A61K38/00
摘要： This invention provides a polypeptide comprising a fragment of a chemokine receptor capable of inhibiting HIV-1 infection. In an embodiment, the chemokine receptor is C-C CKR-5. In another embodiment, the fragment comprises at least one extracellular domain of the chemokine receptor C-C CKR-5. This invention further provides different uses of the chemokine receptor for inhibiting HIV-1 infection.
-
67.发明公开NON-PEPTIDYL MOIETY-CONJUGATED CD4-GAMMA2 AND CD4-IgG2 IMMUNOCONJUGATES, AND USES THEREOF 失效免疫偶联非PEPTIDYLEN部分和CD4 GAMMA2-或CD4-IgG2的部分组成，及其用途。
公开(公告)号：EP0664710A1
公开(公告)日：1995-08-02
申请号：EP93919917.0
申请日：1993-08-06
IPC分类号： G01N33 , A61K38 , A61K39 , A61K47 , A61K51 , A61M36 , A61P31 , C07K14 , C07K16 , C07K17 , C12N5 , C12N15 , C12P21
CPC分类号： C07K16/00 , A61K38/00 , A61K47/6425 , A61K47/6803 , A61K47/6849 , A61K51/10 , A61K51/1093 , C07K14/70514 , C07K2319/00 , C07K2319/30
摘要： This invention provides an immunoconjugate which comprises 1) a non-peptidyl toxin and 2) a CD4-gamma2 chimeric heavy chain homodimer linked thereto. This invention also provides an immunoconjugate which comprises 1) a gamma radiation-emitting radionuclide of low to moderate cytotoxicity and 2) a CD4-gamma2 chimeric heavy chain homodimer linked thereto. This invention further provides an immunoconjugate which comprises 1) a non-peptidyl toxin and 2) a heterotetramer comprising two heavy chains and two light chains, both heavy chains being either a) IgG2 heavy chains or b) chimeric CD4-IgG2 heavy chains, and both light chains being either a) kappa light chains or b) chimeric CD4-kappa light chains. This invention further provides an immunoconjugate which comprises 1) a gamma radiation-emitting radionuclide of low to moderate cytotoxicity and 2) a heterotetramer comprising two heavy chains and two light chains, both heavy chains being either a) IgG2 heavy chains or b) chimeric CD4-IgG2 heavy chains, and both light chains being either a) kappa light chains or b) chimeric CD4-kappa light chains. Finally, this invention provides methods of using the immunoconjugates of the subject invention.
-
公开(公告)号：EP0528011A4
公开(公告)日：1993-06-30
申请号：EP92907272
申请日：1992-02-10
IPC分类号： A61K39/395 , A61K38/00 , A61K47/48 , C07K14/00 , C07K14/73 , C07K16/00 , C07K19/00 , C12N5/10 , C12N15/09 , C12N15/13 , C12P21/02 , G01N33/53 , G01N33/569 , C12N15/00 , A61K39/00 , C07K13/00
CPC分类号： C07K14/70514 , A61K38/00 , A61K47/6875 , C07K16/00 , C07K2319/00 , C07K2319/30
-
公开(公告)号：EP1615646B2
公开(公告)日：2022-07-27
申请号：EP04759349.6
申请日：2004-04-08
IPC分类号： A61K9/08 , A61K47/18 , A61K31/195 , A61K31/485
-
70.发明公开
-
-
-
-
-
-
-
-
-
搜索结果
88 条记录 (耗时 0.024 秒)
